eMC - trusted, up to date and comprehensive information about medicines
Link to eMC medicine guides website
eMC homepage
Get Medicines Compendium UK app here

THE BOOTS COMPANY PLC

1 Thane Road West, Beeston, Nottingham, NG2 3AA
Telephone: +44 (0)1159 595 165
Fax: +44 (0)1159 592 565

Before you contact this company: often several companies will market medicines with the same active ingredient. Please check that this is the correct company before contacting them. Why?


Summary of Product Characteristics last updated on the eMC: 29/06/2010
SPC Gee's Linctus BP


Go to top of the page
1. NAME OF THE MEDICINAL PRODUCT

Opiate Squill Linctus BP/Gee's Linctus BP


Go to top of the page
2. QUALITATIVE AND QUANTITATIVE COMPOSITION

Active ingredients

% v/v

Opium Tincture BP

1.67

Squill Vinegar for Oxymel

10.0

(Equivalent to squill oxymel

camphorated opium tincture)

33.3

33.3


Go to top of the page
3. PHARMACEUTICAL FORM

Oral solution.


Go to top of the page
4. CLINICAL PARTICULARS

Go to top of the page
4.1 Therapeutic indications

For the symptomatic relief of chesty cough.


Go to top of the page
4.2 Posology and method of administration

For oral administration.

Adults and children over 12 years

5ml three to four times daily.

Children under 12 years

Not recommend for children under 12 years unless prescribed by a physician.

Elderly

There is no need for dosage reduction in the elderly.


Go to top of the page
4.3 Contraindications

Hypersensitivity to ingredients. Patients with impaired renal or hepatic function or cardiac disorders. Moderate to severe respiratory depression, acute alcoholism, convulsive disorders, head injuries and conditions in which there is raised intracranial pressure.


Go to top of the page
4.4 Special warnings and precautions for use

Should be used with caution in patients with colitis as there is risk of precipitating toxic megacolon. Should be used with caution in elderly patients as there is a risk of percipitating faecal impaction and intestinal obstruction. Excessive, long term use could induce dependence.

Warning: Do not exceed the stated dose.

If symptoms persist, consult your doctor.

Keep all medicines out of the reach of children.

May cause drowsiness.

This medicinal product contains 60.2g of sucrose. When taken according to the dosage recommendations each 5ml dose supplies up to 1.5g of sucrose. Unsuitable in hereditary fructose intolerance, glucose-galactose malabsorption syndrome or sucrase–isomaltase deficiency. (Sucrose)

Warning: this product contains 18.9% by volume of ethanol.

Each 5ml dose contains 0.76g of alcohol.

Harmful for those suffering from liver disease, alcoholism, epilepsy, brain injury or disease as well as for pregnant women and children.

May modify or increase the effect of other medicines. (Alcohol)


Go to top of the page
4.5 Interaction with other medicinal products and other forms of interaction

Clinically significant interactions may occur in patients taking MAOI's concurrently or within 14 days of such treatment and these reactions may be serious. The depressant effects of morphine may enhance depressants of the central nervous system such as alcohol, anaesthetics, hypnotics, sedatives and phenothiazines.


Go to top of the page
4.6 Pregnancy and lactation

The safety of this product during pregnancy and lactation has not been established.


Go to top of the page
4.7 Effects on ability to drive and use machines

Opiate Squill Linctus may cause drowsiness in certain individuals and may therefore interfere with the ability to drive and to operate machinery.


Go to top of the page
4.8 Undesirable effects

May cause constipation if used over a long period. If hypersensitive to squill could cause violent purging, nausea, vomiting and drowsiness.


Go to top of the page
4.9 Overdose

Nausea, vomiting, constipation, drowsiness – signs of morphine overdose. Treat by aspiration and lavage. In severe cases of overdosage morphine-induced depression may be reversed with the specific opiate antagonist naloxone. Intoxication due to squill glycosides, treat as for digoxin overdose.


Go to top of the page
5. PHARMACOLOGICAL PROPERTIES

Go to top of the page
5.1 Pharmacodynamic properties

Tincture of opium has a suppressant action on the cough centre due to its morphine and codeine content. Squill facilitates removal of mucus from bronchial passageways by virtue of a reflex action on bronchial secretions resulting from irritation of the gastrointestinal tract.


Go to top of the page
5.2 Pharmacokinetic properties

Opioids are readily absorbed from the gastrointestinal tract, and undergo significant first pass metabolism in the liver. The major pathway for detoxification is conjugation with glucuronic acid. Very little morphine is excreted unchanged, it is eliminated by glomerular filtration. 90% of an administered dose is excreted within 24 hours. Codeine is likewise excreted chiefly in the urine.


Go to top of the page
5.3 Preclinical safety data

There are no preclinical data of relevance to the prescriber which are additional to that already included.


Go to top of the page
6. PHARMACEUTICAL PARTICULARS

Go to top of the page
6.1 List of excipients

Tolu flavour solution

Liquid sugar

Honey

Alcohol (96%)

Benzoic acid

Racemic camphor

Star anise oil

Tragacanth powdered

Purified water


Go to top of the page
6.2 Incompatibilities

None stated.


Go to top of the page
6.3 Shelf life

36 months.


Go to top of the page
6.4 Special precautions for storage

None


Go to top of the page
6.5 Nature and contents of container

100, 200, 2000ml amber-coloured glass bottle with a polypropylene screw cap, unfitted or an aluminium pilfer-proof, roll-on cap and a PVC flowed-in liner or a triseal (LDPE/EPE/LDPE) liner.


Go to top of the page
6.6 Special precautions for disposal and other handling

Not applicable


Go to top of the page
7. MARKETING AUTHORISATION HOLDER

The Boots Company PLC

1 Thane Road West

Nottingham NG2 3AA


Go to top of the page
8. MARKETING AUTHORISATION NUMBER(S)

PL00014/5721R


Go to top of the page
9. DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION

Date of first authorisation: 21 July 1989

Renewal of the authorisation: 29 September 2002


Go to top of the page
10. DATE OF REVISION OF THE TEXT

January 2010



More information about this product

Link to this document from your website: http://www.medicines.org.uk/emc/medicine/23201/SPC/


Active Ingredients/Generics

 
   squill vinegar
   opium tincture